AlphaGrep UK’s Ultragenyx Pharmaceutical RARE Stock Holding History

AlphaGrep UK’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,299	Closed	-$362K	–	916
2026 Q1	$362K	Buy	+17,299	New	+$390K	0.1%	423

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

AlphaGrep UK's RARE Position: Q2 2026 in Review

AlphaGrep UK sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 17,299 shares — an estimated $362K sold.

AlphaGrep UK first reported a position in RARE in Q1 2026 and held it in 1 quarter. The position peaked at $362K in Q1 2026. 287 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

AlphaGrep UK reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
AlphaGrep UK sold 17,299 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $362K.
AlphaGrep UK first reported a position in Ultragenyx Pharmaceutical in Q1 2026 and held it in 1 quarter.
AlphaGrep UK's Ultragenyx Pharmaceutical position peaked at $362K in Q1 2026.
287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.